EUVIMEDEUVIMED entdecken
Open Access

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

Ruchi P Patel iD, Guido Ghilardi iD, Yunlin Zhang iD, Yi-Hao Chiang iD, Wei Xie iD, Puneeth Guruprasad, Ki Hyun Kim iD, Inkook Chun, Mathew G Angelos iD, Raymone Pajarillo iD, Seok Jae Hong iD, Yong Gu Lee iD und 39 weitere

Science Immunology · 2024

DOI: 10.1126/sciimmunol.adn6509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Ruchi P Patel und 50 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, CD5 Antigens, T-Lymphocytes. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveCD5 AntigensT-LymphocytesAnimalsMiceHumansReceptors, Chimeric AntigenCell Line, TumorCRISPR-Cas SystemsFemale

Substanzen

CD5 AntigensReceptors, Chimeric AntigenCd5 protein, mouse

Autor:innen und Institutionen

  • Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Hematology and Oncology, Hospital of University of Pennsylvania, Philadelphia, PA, USA.
  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Hematology and Oncology, MacKay Memorial Hospital, Taipei, Taiwan.
  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea.

ORCID-Profile: Ruchi P Patel, Guido Ghilardi, Yunlin Zhang, Yi-Hao Chiang, Wei Xie, Ki Hyun Kim, Mathew G Angelos, Raymone Pajarillo, Seok Jae Hong, Yong Gu Lee, Trang Vu, Adam E Snook, Nicholas Siciliano, Antonia Rotolo, Arati Inamdar, Jaryse Harris, Alberto Carturan, Luca Paruzzo, Hatcher J Ballard, Mohamed Abdel-Mohsen, Khatuna Gabunia, Maria Wysocka, Gerald P Linette, David T Teachey, Avery D Posey, Daniel J Powell, C Tor Sauter, Stefano Pileri, John Scholler, Alain H Rook, Stephen J Schuster, Stefan K Barta, Patrizia Porazzi, Marco Ruella

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Patel, R. P., Ghilardi, G., Zhang, Y., Chiang, Y. H., Xie, W., Guruprasad, P., Kim, K. H., Chun, I., Angelos, M. G., Pajarillo, R., Hong, S. J., Lee, Y. G., Shestova, O., Shaw, C., Cohen, I., Gupta, A., Vu, T., Qian, D., Yang, S., …, & Ruella, M. (2024). CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Science Immunology. https://doi.org/10.1126/sciimmunol.adn6509

Vancouver

Patel RP, Ghilardi G, Zhang Y, Chiang YH, Xie W, Guruprasad P, et al. CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Science Immunology. 2024. doi:10.1126/sciimmunol.adn6509

BibTeX
@article{Patel2024,
  author = {Patel, Ruchi P and Ghilardi, Guido and Zhang, Yunlin and Chiang, Yi-Hao and Xie, Wei and Guruprasad, Puneeth and Kim, Ki Hyun and Chun, Inkook and Angelos, Mathew G and Pajarillo, Raymone and Hong, Seok Jae and Lee, Yong Gu and Shestova, Olga and Shaw, Carolyn and Cohen, Ivan and Gupta, Aasha and Vu, Trang and Qian, Dean and Yang, Steven and Nimmagadda, Aditya and Snook, Adam E and Siciliano, Nicholas and Rotolo, Antonia and Inamdar, Arati and Harris, Jaryse and Ugwuanyi, Ositadimma and Wang, Michael and Carturan, Alberto and Paruzzo, Luca and Chen, Linhui and Ballard, Hatcher J and Blanchard, Tatiana and Xu, Chong and Abdel-Mohsen, Mohamed and Gabunia, Khatuna and Wysocka, Maria and Linette, Gerald P and Carreno, Beatriz and Barrett, David M and Teachey, David T and Posey, Avery D and Powell, Daniel J and Sauter, C Tor and Pileri, Stefano and Pillai, Vinodh and Scholler, John and Rook, Alain H and Schuster, Stephen J and Barta, Stefan K and Porazzi, Patrizia and Ruella, Marco},
  title = {CD5 deletion enhances the antitumor activity of adoptive T cell therapies},
  journal = {Science Immunology},
  year = {2024},
  doi = {10.1126/sciimmunol.adn6509}
}
Kostenlos starten →